Relyvrio’s Failure Sparks NeuroSense ALS Development Changes

 
• By Derrick Gingery
  
neuron-degeneration
NeuroSense is planning a Phase III study for its ALS candidate PrimeC. • Source: Shutterstock

More from Clinical Trials

More from R&D